Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,344 from $1,327 and keeps an Overweight rating on the shares. The firm sees Eli Lilly’s Q1 results and upgraded 2026 guidance as supportive of its positive outlook for the company’s GLP-1 franchise and the global growth/development of the obesity market.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly price target raised to $1,230 from $1,205 at Cantor Fitzgerald
- Eli Lilly Earnings Call Signals Hypergrowth Momentum
- Unusually active option classes on open April 30th
- FDA proposes to exclude semaglutide, tirzepatide on 503B bulks list
- Midday Fly By: Alphabet, Meta, Amazon, Microsoft report quarterly beats